Implantable particles for the treatment of gastroesophageal reflux disease
View Patent ↗The invention encompasses the treatment of urinary incontinence, gastroesophageal reflux disease and the amelioration of skin wrinkles using biocompatible hydrophilic cationic microparticles and a cell adhesion promoter.
1. A method for treating gastroesophageal reflux disease, which comprises implanting into the lower esophageal sphincter or the diaphragm of a mammal in need of such treatment a therapeutically effective tissue-bulking amount of microparticles, wherein the microparticles comprise a biocompatible, non-toxic hydrophilic copolymer, which comprises in copolymerized form about 25% to about 99% by weight of neutral hydrophilic acrylic monomer, about 2% to about 30% by weight of one or more monomers having a cationic charge, and about 1% to about 30% by weight of a functionalized monomer.
2. The method of claim 1 , wherein the microparticles are cationic.
3. The method of claim 1 , wherein the microparticles comprise a positive charge on their surface.
4. The method of claim 1 , wherein said mammal is a human.
5. The method of claim 1 , wherein the microparticles are coated with or linked to at least one collagen or a derivative thereof, glucosaminoglycans, or a mixture thereof.
6. The method of claim 1 , wherein the microparticles are implanted in a sterile and pyrogen-free injectable solution.
7. The method of claim 1 , wherein the microparticles are spherical.
8. The method of claim 7 , wherein said microparticles have diameters ranging from about 10 μm to about 1000 μm.
9. The method of claim 1 , wherein said implantation is made via syringe, catheter, or combinations thereof.
10. The method of claim 1 , wherein said microparticles comprise or are implanted with one or more of a therapeutic agent, an anti-inflammatory agent, an angiogenesis inhibitor, a radioactive element, and an antimitotic agent.
11. The method of claim 1 , wherein the microparticles further comprise a cell adhesion promoter.
12. The method of claim 11 , wherein said cell adhesion promoter is selected from the group consisting of fibronectin, laminin, chondronectin, entacin, epibolin, liver cell adhesion molecule, serum spreading factor, collagen, heparin sulfates, dermatan sulfates, chonodroctin sulfates, glucosaminoglycans, and mixtures thereof.
13. A method for treating gastroesophageal reflux disease, which comprises:
(a) preparing cationic microparticles which comprise a biocompatible, non-toxic and hydrophilic copolymer, which comprises in copolymerized form about 25% to about 99% by weight of neutral hydrophilic acrylic monomer, about 2% to about 30% by weight of one or more monomers having a cationic charge, and about 1% to about 30% by weight of a functionalized monomer;
(b) administering the resulting microparticles to a mammal by implantation into a sphincter located where the esophagus meets the stomach.
14. The method of claim 13 , wherein the microparticles further comprise a cell adhesion promoter.
15. The method of claim 14 , wherein the cell adhesion promoter is selected from the group consisting of fibronectin, laminin, chondronectin, entacin, epibolin, liver cell adhesion molecule, serum spreading factor, collagen, heparin sulfates, dermatan sulfates, chonodroctin sulfates, glucosaminoglycans, and mixtures thereof.
16. The method of claim 11 , wherein the cell adhesion promoter is coated on the microparticles.
17. The method of claim 14 , wherein the cell adhesion promoter is coated on the microparticles.